Want to see MBRX full AI Analyst Report?
MBRX Stock Chart & Stats
$0.61
$0.04(1.92%)
At close: 4:00 PM EDT
$0.61
$0.04(1.92%)
Day’s Range― - ―
52-Week Range$0.16 - $15.77
Previous CloseN/A
Volume44.49K
Average Volume (3M)1.83M
Market Cap
$14.61M
Enterprise Value$8.88
Total Cash (Recent Filing)$7.26M
Total Debt (Recent Filing)$292.00K
Price to Earnings (P/E)―
Beta1.08
Next Earnings
Mar 19, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-17.13
Shares Outstanding19,477,380
10 Day Avg. Volume599,922
30 Day Avg. Volume1,826,047
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.26
Price to Sales (P/S)0.00
P/FCF Ratio-0.17
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$12.00Price Target Upside1867.21% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-3.69
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Promising Annamycin EfficacyThe reported remission activity in relapsed or refractory AML provides clinical validation for Annamycin in a high-need setting. Similar results among patients who failed venetoclax could broaden the addressable treatment opportunity if later data confirm the preliminary findings.
Potential Differentiation Through SafetyA lack of observed cardiotoxicity may help distinguish Annamycin from established anthracycline-based approaches, supporting its clinical positioning if durability and efficacy are confirmed. This safety profile could also improve physician adoption and strengthen future partnering discussions.
Low Financial LeverageMinimal debt reduces solvency pressure and avoids substantial interest or refinancing obligations while the company funds clinical development. Although the business remains dependent on equity capital, low leverage preserves greater flexibility than a similarly loss-making company carrying significant debt.
Bears Say
Pre-commercial Operating ModelThe absence of product revenue means the company has not yet demonstrated commercial demand or operating leverage. Persistent losses leave future financial performance dependent on successful clinical development, regulatory progress, and eventual commercialization or partnering.
Persistent Cash BurnSustained negative cash generation shows that research and clinical operations are not self-funded. Continued burn will require additional financing or other capital sources, creating ongoing execution risk and potentially limiting the pace or scope of development if funding becomes less available.
Capital Erosion And DilutionThe shrinking equity base reflects the cumulative effect of ongoing losses, while new shares and warrants can dilute existing holders as development continues. Repeated reliance on equity financing may increase the cost of capital and leave shareholders exposed to further ownership erosion.
Moleculin Biotech News
MBRX FAQ
What was Moleculin Biotech’s price range in the past 12 months?
Moleculin Biotech lowest stock price was $0.16 and its highest was $15.77 in the past 12 months.
What is Moleculin Biotech’s market cap?
Moleculin Biotech’s market cap is $14.61M.
When is Moleculin Biotech’s upcoming earnings report date?
Moleculin Biotech’s upcoming earnings report date is Mar 19, 2027 which is in 189 days.
How were Moleculin Biotech’s earnings last quarter?
Moleculin Biotech released its earnings results on Aug 14, 2026. The company reported -$1.4 earnings per share for the quarter, beating the consensus estimate of -$1.553 by $0.153.
Is Moleculin Biotech overvalued?
According to Wall Street analysts Moleculin Biotech’s price is currently Undervalued.
Does Moleculin Biotech pay dividends?
Moleculin Biotech does not currently pay dividends.
What is Moleculin Biotech’s EPS estimate?
Moleculin Biotech’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Moleculin Biotech have?
Moleculin Biotech has 19,477,380 shares outstanding.
What happened to Moleculin Biotech’s price movement after its last earnings report?
Moleculin Biotech reported an EPS of -$1.4 in its last earnings report, beating expectations of -$1.553. Following the earnings report the stock price went up 7.18%.
Which hedge fund is a major shareholder of Moleculin Biotech?
Currently, no hedge funds are holding shares in MBRX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Moleculin Biotech
Moleculin Biotech, Inc. is a clinical-stage pharmaceutical company dedicated to advancing therapeutic candidates designed to combat highly aggressive cancers and viral infections. Their primary investigational drug, Annamycin, is currently undergoing Phase 1/2 clinical trials. These trials aim to assess its efficacy against acute myeloid leukemia (AML) that has relapsed or is resistant to prior therapies, as well as malignancies that have spread to the lungs. WP1066, a prominent immune/transcription modulator for the company, is presently in Phase I studies, targeting both adult and pediatric brain tumors, pancreatic cancer, and other types of aggressive malignancies. Further, the firm is developing WP1220, an analog of WP1066, intended for topical application in treating cutaneous T-cell lymphoma. Another compound, WP1122, is under development for glioblastoma multiforme and COVID-19. Moleculin Biotech has established collaboration agreements and partnerships with organizations such as MD Anderson, Animal Life Sciences, LLC, and WPD Pharmaceuticals Sp z.o.o. The company was founded in 2015 and maintains its principal offices in Houston, Texas.
MBRX Stock 12 Month Forecast
Average Price Target
$12.00
▲(1867.21% Upside)
Technical Analysis
Ownership Overview
5.44% Insiders
0.15% Mutual Funds
<0.01% Other Institutional Investors
94.19% Public Companies and
Individual Investors